article thumbnail

Engineering A Healthier Future: The Power of Tissue Regeneration

Roots Analysis

The Art and Science of Tissue Engineering Do you know that scientists are now able to grow body parts in the lab? This incredible medical breakthrough is called tissue engineering. So, what is tissue engineering? Having said that regenerative grafts created using tissue engineering have numerous applications.

article thumbnail

Reimagining cell engineering with picodroplet microfluidic technology

Drug Discovery World

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Cell engineering is being held back by lengthy and complicated multi-step workflows. Sphere Fluidics’ Cyto-Mine ® system offers a streamlined, automated solution to this challenge using picodroplet microfluidic technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Development and Manufacturing of Primary Packaging and Medical Devices

Pharmaceutical Technology

Packaging plays a critical part in the pharmaceuticals and medical devices industries and is developed with its own set of security standards for the safety of consumers. Furthermore, the rising demand for sustainable packaging solutions is gradually opening a new avenue in the primary packaging market.

Packaging 130
article thumbnail

Machine learning: A useful tool in the development of next generation antibody therapeutics

Drug Discovery World

Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. These generative models will create a small, highly confident group of candidates with high binding efficacy and developability.

article thumbnail

Quell Therapeutics and AstraZeneca partner on Treg cell therapies

Pharmaceutical Technology

Quell Therapeutics and AstraZeneca have entered a collaboration, exclusive option and licence deal for the development, manufacturing and commercialisation of engineered T-regulator (Treg) cell therapies for autoimmune diseases. AstraZeneca will make an upfront payment to Quell of $85m, mostly in cash.

Engineer 130
article thumbnail

US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410

Pharmaceutical Technology

INB-400, an autologous, genetically engineered gamma-delta T cell therapy, is the company’s DeltEx chemotherapy-resistant autologous and allogeneic drug-resistant immunotherapy (DRI) technology. We eagerly anticipate enrolling our first Phase II patients for INB-400 later this year.”

article thumbnail

‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process

STAT News

As the Covid-19 pandemic spread across the world two years ago, one of India’s leading biotech companies was racing to develop a vaccine with crucial backing from the Indian government.